News Releases

Date	Title	Additional Formats
November 23, 2021	Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference
November 12, 2021	Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
November 8, 2021	Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
October 27, 2021	Phathom Pharmaceuticals Withdraws Public Offering
October 26, 2021	Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock
October 24, 2021	Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
October 21, 2021	Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
October 18, 2021	Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
September 27, 2021	Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
September 20, 2021	Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital